Literature DB >> 19380520

Endocrine dysfunction in p27Kip1 deficient mice and susceptibility to Wnt-1 driven breast cancer.

Cynthia E Glover1, Kay E Gurley, Kyung-Hoon Kim, Barry Storer, Mathew L Fero, Christopher J Kemp.   

Abstract

The cyclin-dependent kinase (Cdk) inhibitor p27(Kip1) (p27) is a marker of prognosis in many cancers, including breast cancer. Low p27 expression correlates with poor prognosis, especially in hormone receptor positive breast tumors. This association suggests a role for p27 in hormone-dependent cancer. We used the Wnt-1 transgenic mouse model to further explore the role of p27 in hormone-driven breast cancer. We found that p27 deficiency did not alter breast cancer rate in either male or female Wnt-1 mice. However, we did find p27-/- females had reduced levels of serum progesterone (P) and increased variability in estradiol (E), which could have affected their cancer susceptibility. To equalize hormone levels, an additional cohort of Wnt-1 female mice was ovariectomized and implanted with slow release pellets of E and P. Although this treatment did not alter the breast cancer rate, it did accelerate the development of pituitary and gastric tumors in p27-/- mice. This study shows that while not a significant inhibitor of Wnt-1-driven breast cancer, p27 inhibits gastric tumors, whose latency is modulated by sex steroids.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19380520      PMCID: PMC2691144          DOI: 10.1093/carcin/bgp089

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  46 in total

Review 1.  Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk.

Authors:  M C Pike; D V Spicer; L Dahmoush; M F Press
Journal:  Epidemiol Rev       Date:  1993       Impact factor: 6.222

2.  Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.

Authors:  N Kawamata; R Morosetti; C W Miller; D Park; K S Spirin; T Nakamaki; S Takeuchi; Y Hatta; J Simpson; S Wilcyznski
Journal:  Cancer Res       Date:  1995-06-01       Impact factor: 12.701

3.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

4.  A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice.

Authors:  M L Fero; M Rivkin; M Tasch; P Porter; C E Carow; E Firpo; K Polyak; L H Tsai; V Broudy; R M Perlmutter; K Kaushansky; J M Roberts
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

5.  Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1).

Authors:  H Kiyokawa; R D Kineman; K O Manova-Todorova; V C Soares; E S Hoffman; M Ono; D Khanam; A C Hayday; L A Frohman; A Koff
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  Expression of the int-1 gene in transgenic mice is associated with mammary gland hyperplasia and adenocarcinomas in male and female mice.

Authors:  A S Tsukamoto; R Grosschedl; R C Guzman; T Parslow; H E Varmus
Journal:  Cell       Date:  1988-11-18       Impact factor: 41.582

7.  Cytoplasmic mislocalization of p27Kip1 protein is associated with constitutive phosphorylation of Akt or protein kinase B and poor prognosis in acute myelogenous leukemia.

Authors:  Yoo Hong Min; June-Won Cheong; Ji Yeon Kim; Ju In Eom; Seung Tae Lee; Jee Sook Hahn; Yun Woong Ko; Mark Hong Lee
Journal:  Cancer Res       Date:  2004-08-01       Impact factor: 12.701

8.  Assignment of the human p27Kip1 gene to 12p13 and its analysis in leukemias.

Authors:  J A Pietenpol; S K Bohlander; Y Sato; N Papadopoulos; B Liu; C Friedman; B J Trask; J M Roberts; K W Kinzler; J D Rowley
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

9.  Distinct roles for p53, p27Kip1, and p21Cip1 during tumor development.

Authors:  Jeannette Philipp-Staheli; Kyung-Hoon Kim; Denny Liggitt; Kay E Gurley; Gary Longton; Christopher J Kemp
Journal:  Oncogene       Date:  2004-01-29       Impact factor: 9.867

10.  Estrogens down-regulate p27Kip1 in breast cancer cells through Skp2 and through nuclear export mediated by the ERK pathway.

Authors:  James S Foster; Romaine I Fernando; Noriko Ishida; Keiichi I Nakayama; Jay Wimalasena
Journal:  J Biol Chem       Date:  2003-08-06       Impact factor: 5.157

View more
  5 in total

1.  Luteolin and gefitinib regulation of EGF signaling pathway and cell cycle pathway genes in PC-3 human prostate cancer cells.

Authors:  Barry M Markaverich; Mary Vijjeswarapu; Kevin Shoulars; Mary Rodriguez
Journal:  J Steroid Biochem Mol Biol       Date:  2010-06-15       Impact factor: 4.292

Review 2.  The function of p27 KIP1 during tumor development.

Authors:  Jinhwa Lee; Sung Soo Kim
Journal:  Exp Mol Med       Date:  2009-11-30       Impact factor: 8.718

3.  An essential role of p27 downregulation in fenvalerate-induced cell growth in human uterine leiomyoma and smooth muscle cells.

Authors:  Xiaohua Gao; Linda Yu; Lysandra Castro; Charles J Tucker; Alicia B Moore; Hang Xiao; Darlene Dixon
Journal:  Am J Physiol Endocrinol Metab       Date:  2012-07-31       Impact factor: 4.310

4.  The Cks1/Cks2 axis fine-tunes Mll1 expression and is crucial for MLL-rearranged leukaemia cell viability.

Authors:  William Grey; Adam Ivey; Thomas A Milne; Torsten Haferlach; David Grimwade; Frank Uhlmann; Edwige Voisset; Veronica Yu
Journal:  Biochim Biophys Acta Mol Cell Res       Date:  2017-09-20       Impact factor: 4.739

5.  Genetic characterization of p27(kip1) and stathmin in controlling cell proliferation in vivo.

Authors:  Stefania Berton; Ilenia Pellizzari; Linda Fabris; Sara D'Andrea; Ilenia Segatto; Vincenzo Canzonieri; Daniela Marconi; Monica Schiappacassi; Sara Benevol; Valter Gattei; Alfonso Colombatti; Barbara Belletti; Gustavo Baldassarre
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.